Possible new therapeutic agents for malignant pleural mesothelioma: anti-CD26 monoclonal antibody and naftopidil

References

• Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–2644.
   PubMed Web of Science ®Google Scholar
• Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405–1414.
   PubMed Web of Science ®Google Scholar
• Eguchi R, Nakano T, Wakabayashi I. Progranulin and granulin-like protein as novel VEGF-independent angiogenic factors derived from human mesothelioma cells. Oncogene. 2016 Jun 27; doi:10.1038/onc.2016.226. [Epub ahead of print].
   PubMedGoogle Scholar
• Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer. 2008;44(1):46–53.
   PubMed Web of Science ®Google Scholar
• Hassan R, Kindler HL, Jahan T, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014;20(23):5927–5936.
   PubMed Web of Science ®Google Scholar
• Alley EW, Schellens JHM, Santoro A, et al. Single-agent pembrolizumab for patients with malignant pleural mesothelioma (MPM). J Thor Oncol. 2015;10(suppl 2).
   Google Scholar
• Rasmussen HB, Branner S, Wiberg FC, et al. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol. 2003;10(1):19–25.
   PubMedGoogle Scholar
• Takasawa W, Ohnuma K, Hatano R, et al. Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines. Biochem Biophys Res Commun. 2010;401(1):7–12.
   PubMed Web of Science ®Google Scholar
• Beckenkamp A, Davies S, Willig JB, et al. DPPIV/CD26: a tumor suppressor or a marker of malignancy? Tumour Biol. 2016;37(6):7059–7073.
   PubMed Web of Science ®Google Scholar
• Amritha CA, Kumaravelu P, Chellathai DD. Evaluation of anti-cancer effects of DPP-4 inhibitors in colon cancer; an in vitro study. J Clin Diagn Res. 2015;9(12):14–16.
   Google Scholar
• Barreira Da Silva R, Laird ME, Yatim N, et al. Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nat Immunol. 2015;16(8):850–858.
   PubMed Web of Science ®Google Scholar
• Aoe K, Amatya VJ, Fujimoto N, et al. CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma. Clin Cancer Res. 2012;18:1447–1456.
   PubMed Web of Science ®Google Scholar
• Inamoto T, Yamada T, Ohnuma K, et al. Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin Cancer Res. 2007;13:4191–4200.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Madokoro H, Yamada K, et al. A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition. Cancer Cell Int. 2016;16:35.
   PubMed Web of Science ®Google Scholar
• Wesley UV, McGroarty M, Homoyouni A. Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Res. 2005;65(4):1325–1334.
   PubMed Web of Science ®Google Scholar
• Yamada K, Hayashi M, Madokoro H, et al. Nuclear localization of CD26 induced by a humanized monoclonal antibody inhibits tumor cell growth by modulating of POLR2A transcription. PLoS One. 2013;8(4):e62304.
   PubMed Web of Science ®Google Scholar
• Angevin E, Isambert N, Trillet-Lenoir VT, et al. First-in-human phase I administration of YS110, a monoclonal antibody directed against the CD26 immunostimulatory molecule in advanced cancer patients. J Clin Oncol. 2015;33(suppl; abstr 2519).
   Google Scholar
• Saxena A, Becker D, Preeshagul I, et al. Therapeutic effects of repurposed therapies in non-small cell lung cancer: what is old is new again. Oncologist. 2015;20(8):934–945.
   PubMed Web of Science ®Google Scholar
• Wang HM, Liao ZX, Komaki R, et al. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol. 2013;24(5):1312–1319.
   PubMed Web of Science ®Google Scholar
• Wang H, Liao Z, Zhuang Y, et al. Incidental receipt of cardiac medications and survival outcomes among patients with stage III non-small-cell lung cancer after definitive radiotherapy. Clin Lung Cancer. 2015;16(2):128–136.
   PubMed Web of Science ®Google Scholar
• Yamada D, Nishimatsu H, Kumano S, et al. Reduction of prostate cancer incidence by naftopidil, an α1 -adrenoceptor antagonist and transforming growth factor-β signaling inhibitor. Int J Urol. 2013;20(12):1220–1227.
   PubMed Web of Science ®Google Scholar
• Iwamoto Y, Ishii K, Sasaki T, et al. Oral naftopidil suppresses human renal-cell carcinoma by inducing G1 cell-cycle arrest in tumor and vascular endothelial cells. Cancer Prev Res (Phila). 2013;6(9):1000–1006.
   PubMed Web of Science ®Google Scholar
• Masachika E, Kanno T, Nakano T, et al. Naftopidil induces apoptosis in malignant mesothelioma cell lines independently of α1-adrenoceptor blocking. Anticancer Res. 2013;33(3):887–894.
   PubMed Web of Science ®Google Scholar
• Mikami K, Nagaya H, Gotoh A, et al. Naftopidil is useful for the treatment of malignant pleural mesothelioma. Pharmacology. 2014;94(3–4):163–169.
   PubMed Web of Science ®Google Scholar
• Kanno T, Tanaka A, Shimizu T, et al. 1-[2-(2-Methoxyphenylamino)ethylamino]-3-(naphthalene-1-yloxy)propan-2-ol as a potential anticancer drug. Pharmacology. 2013;91(5–6):339–345.
   PubMed Web of Science ®Google Scholar
• Kaku Y, Nagaya H, Tsuchiya A, et al. Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma. Cancer Sci. 2014;105(7):883–889.
   PubMed Web of Science ®Google Scholar